Fund Manager Summary on Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)
In February 2026, Firetrail Investments commented that Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) is a recurring-revenue hospital respiratory business gaining share as clinical evidence supports nasal cannula therapy, with growth, earnings momentum and a relatively low valuation underpinning its appeal. Overall, fund manager commentary on FPH is constructive and has become more positive in recent months, with the consensus highlighting a high-quality medical device franchise with strong structural tailwinds from ageing respiratory demand, expanding clinical adoption, premium new products, and a heavily recurring consumables base that supports resilience and margin expansion. Managers pointed to record FY2025 and strong HY26 results, improving gross and operating margins, net cash, robust R&D investment and a long runway for international adoption, especially in hospital therapies such as Optiflow and anaesthesia applications, while also noting that operational execution remains strong. The main risks raised are external rather than business-model driven: tariff exposure because manufacturing is offshore, possible US trade-policy changes, seasonal swings in respiratory demand and slower-than-expected conversion of clinicians and hospital protocols, which can delay uptake despite clear patient and cost benefits. Recent commentary suggests the strategic debate is less about product quality and more about how quickly FPH can convert evidence into guideline changes and sustain growth through new launches, geographic expansion and continued operating leverage.
Commentary From The Managers
There are 21 insights from 9 fund managers regarding their investment in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) available on Thesis Tracker.
Unlock Updates With ThesisTracker Pro
Don’t let information asymmetry undermine your investment returns. Join other engaged investors on ThesisTracker Pro.
Updates are made available to members within 12 hours of being released. The completeness, accuracy or current status of the investments referenced are not guaranteed.
Commentary From The Managers
The completeness, accuracy or current status of the investments referenced are not guaranteed.
Frequently Asked Questions
Who is investing in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)?
Fund managers including Centennial Asset Management, Oracle Advisory Group, ELM Responsible Investments, Selector Funds Management, Flagship Investments, Hyperion Asset Management, Ten Cap, Paradice Investment Management and Firetrail Investments have invested in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH).
Why do fund managers invest in Fisher & Paykel Healthcare Corporatn Ltd?
Fund managers are attracted to Fisher & Paykel Healthcare because it has a leading position in respiratory and acute care, with recurring revenue from consumables and accessories and exposure to hospital and homecare demand. Recent reports highlight strong revenue and profit growth, new product rollouts, improving margins and steady R&D investment. The business also has a net cash balance and dividend support, but investors weigh these strengths against tariff and regulatory risks and the slower pace of clinical adoption.
What happened to Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)?
Fisher & Paykel Healthcare is attracting investment due to its strong financial performance, marked by a 14% revenue growth to NZ$1.09 billion in HY26, driven by robust demand in both hospital and homecare segments. The company is well-positioned to benefit from an anticipated increase in respiratory product demand in the U.S., as a decline in vaccination rates raises potential earnings forecasts. Additionally, ongoing improvements in operational efficiency led to higher margins, and the upward revision of FY26 revenue and NPAT guidance reflects confidence in sustained growth.
What is the short interest in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH)?
The short interest in Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) is 0.08% which makes it the 424th most shorted stock on the ASX. Of the 587.3M shares that Fisher & Paykel Healthcare Corporatn Ltd has on issue, 485.1K have been sold short.
What does Fisher & Paykel Healthcare Corporatn Ltd (ASX:FPH) do?
Fisher & Paykel Healthcare Corp. Ltd. engages in the design, manufacture, and marketing of products and systems for use in acute and chronic respiratory care, surgery, and treatment of obstructive sleep apnea. It operates through the following geographical segments: North America, Europe, Asia Pacific, and Other. The Other segment includes New Zealand, Latin America, Africa, and the Middle East. The company was founded in 1969 and is headquartered in Auckland, New Zealand.